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Abstract
Background: The daily diary Urticaria Activity Score (UAS) and its weekly score (UAS7) are widely used to assess
signs and symptoms in patients with chronic spontaneous urticaria (CSU). The objective of this study was to assess
the psychometric properties of a Spanish version of the once-daily UAS.
Methods: Observational study in patients ≥18 years old receiving usual care for CSU (daily or almost daily occurrence
of generalized hives or angioedema for ≥6 weeks). Patients were included consecutively and completed the UAS, EQ-
5D, and the Chronic Urticaria Quality of Life scale (CU-Q2oL) at two study visits 6 weeks apart. On each occasion, the
UAS was completed once-daily for 7 consecutive days to be able to calculate the UAS7 score. Psychometric properties
of reliability, construct validity, and responsiveness were assessed. The Minimal Important Difference (MID) was
estimated for the UAS7 using anchor- and distribution-based approaches.
Results: Data from 166 patients was available for analysis (mean age 49 years, 65.7% female). Floor (5.4% of patients
with the lowest possible score) and ceiling (1.2%) effects were low; 15% of patients had missing values. Internal
consistency and test-retest reliability were good (Cronbach’s alpha of 0.83 and an ICC of 0.84, respectively). Convergent
validity was demonstrated through the pattern of correlations with the EQ-5D and CU-Q2oL and known groups’ validity
was demonstrated by the instrument’s ability to discriminate between patients with different overall levels of urticaria
severity, with between-group effect-sizes (ES) ranging from 0.36 to 1.19. The UAS7 proved responsive to change with
effect sizes ranging from 0.3 to 1.52 in patients reporting improvement or deterioration in overall urticaria status. The MID
for the UAS7 score was estimated at 7–8 points, on a scale of 0–42.
Conclusions: The Spanish version of the UAS score has demonstrated a robust psychometric performance in patients
with CSU managed in conditions of usual care. It can therefore be considered a suitable instrument to assess disease
activity in clinical practice in Spanish-speaking patients. The Spanish version’s reliability and validity are similar to those
reported for other language versions of the once- and twice-daily variants of the UAS.
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Background
Chronic urticaria (CU) is a mast-cell-driven disease
characterized by the development of hives, angioedema,
or both. The chronic form of the disease is differentiated
from the more acute form by duration, with CU typically
characterized by the development of repeated episodes
of hives for more than six weeks [1]. Chronic urticaria
can be classified as spontaneous (or idiopathic) or as in-
ducible and several sub-types of urticaria exist and may
co-present. Prevalence of CU in the Spanish population
has been calculated at approximately 0.6% with a signifi-
cantly higher prevalence in women than in men [2].
Approximately 9% of cases were found to last from one
to 5 years and 11.3%, for more than 5 years [2].
Several studies have shown that urticaria can have a
significant negative impact on patients’ health-related
quality of life (HRQOL), with patients reporting prob-
lems attributable to their skin condition in many areas
of everyday life, including personal care, recreation and
social interaction, mobility, sleep, and work [3–5]. In
comparison with reference groups from the general
population, patients with CU scored worse on all do-
mains of the SF-36 instrument as well as having poorer
scores on several domains than patients with respiratory
allergy. Their scores on a life satisfaction scale were also
affected [6].
The Urticaria Activity Score (UAS) is a commonly used
patient reported outcome (PRO) measure that assesses
the symptoms (itch) and signs (hives) of CSU. The UAS7
score is calculated as the sum over 7 days of the daily in-
tensity of itch (itch severity score) and number of hives
score (range: 0–42), with higher scores denoting greater
disease activity [7, 8]. The UAS7 has been recommended
by the guidelines for use in clinical practice to determine
disease activity and response to treatment [7]. Currently,
the UAS7 score can be computed using the twice-daily or
the once-daily UAS questionnaires. The once-daily UAS
was validated in German patients in an observational
study [9] while the twice-daily UAS patient assessment
has been accepted by the United States’ Federal Drug
Administration (FDA) as a PRO supporting a label claim
for drugs in CSU and validated as per FDA guidelines for
PRO instruments using data from several clinical trials
[10, 11]. As part of the validation study of the twice daily
version of the UAS, the Minimal Important Difference
(MID) was calculated in patients with chronic spontan-
eous urticaria (CSU) treated with omalizumab or placebo
in a randomized, double-blind, placebo-controlled trial
[11] and confirmed in a later study [12].
To date, the UAS once-daily version and corresponding
UAS7 has not been adapted and validated for use specifi-
cally in a Spanish-speaking population and no MID has
been estimated for that version in conditions of usual cli-
nical practice. It is important to test the psychometric
properties of linguistically adapted versions of a question-
naire to guarantee that the new version shows adequate
reliability, validity and responsiveness. The objective of
this study was therefore to evaluate the psychometric
properties of a Spanish version of the once-daily UAS and
the corresponding UAS7 in patients with CSU managed
according to usual clinical practice and to provide an
estimate of a MID for that version. We hypothesised that
the Spanish version of the UAS and UAS7 would show in-
ternal consistency and test-retest reliability coefficients
over 0.70 wich is a good indicator of reliability, good con-
vergent validity with other disease-specific and generic
measures of HRQOL, ability to discriminate between
groups defined by patient self-ratings of overall urticaria
severity and clinician ratings of the disease, and that it
would be responsive to self- and clinician-perceived
change in disease activity.
Methods
Study design and patient population
This was an observational, prospective, multicentre
study conducted in the dermatology and allergy depart-
ments of several Spanish hospitals under conditions of
usual clinical practice. Data collection was performed
between October 2013 and May 2014. Patients were in-
cluded consecutively in the study if they were ≥ 18 years
of age with a diagnosis of CSU, defined as the daily or
almost daily occurrence of generalized hives or angio-
edema for at least 6 weeks prior to inclusion. Patients
were excluded from the study if they had acute urticaria,
urticaria vasculitis or other forms of urticaria not associ-
ated with the chronic form of the disease, any form of
inducible CU that was not associated with CSU, angio-
edema without the presence of hives, pruritus related to
dermatitis or other skin disease, any systemic disease or
other conditions which might hinder data collection or
interpretation. All patients included in the study gave
their written informed consent to participate. Patients
were followed up for a period of 6 weeks from inclusion
in the study and were managed according to the criteria
of the attending physician following their usual practice.
Patient-reported outcomes measures (PROM)
The once-daily UAS measures urticaria activity in terms of
itch severity and number of hives over the past 24 h. Re-
sponse options for itch severity are 0 =None, 1 =Mild
(present but not annoying or troublesome), 2 =Moderate
(troublesome but does not interfere with normal daily activ-
ity or sleep), 3 = Intense (severe itching, which is sufficiently
troublesome to interfere with normal daily activity or sleep).
Response options for hives are 0 =None, 1 =Mild (< 20
hives/24 h), 2 =Moderate (20–50 hives/24 h), 3 = Intense
(> 50 hives/24 h or large confluent areas of hives). Scores
on these two items are summed to create a total daily UAS
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score (range: 0–6 points). A Spanish version of the instru-
ment was produced for use in the present study following
standard procedures of translation and cultural adaptation
of patient reported outcome (PRO) measures [13]. The
version is shown in Appendix.
Patients completed the UAS over 7 days following the
first visit and in the week prior to the second visit.
Patients were asked to complete the questionnaire just
before going to bed in the evening. Summing daily
non-missing values UAS scores over the seven-day
period provides the UAS7 score, with a score range from
0 (no activity) to 42 (most intense activity).
Other PROs included in the study were the Chronic Urti-
caria Quality of Life scale (CU-Q2oL) and EQ-5D-3 L. The
CU-Q2oL is a disease-specific HRQOL questionnaire for
use in patients with chronic urticaria [14]. It consists of 23
items assessing HRQOL in 6 dimensions: itching (2
questions), swelling (2 questions), impact on daily activities
(6 questions), sleep problems (5 questions), limitations (3
questions) and aesthetic problems (5 questions). Questions
are answered on a 5-point Likert scale and scores are trans-
formed to a 0 to 100 scale, with higher scores indicating
poorer quality of life. The questionnaire generates both an
overall score and scores by dimension and has been vali-
dated in Spanish [15].
The EQ-5D-3 L is a widely used generic question-
naire designed to assess health status in a wide range
of conditions in adult populations [16]. It consists of
5 dimensions (mobility, personal care, daily activities,
pain/discomfort, and anxiety/depression) with three
possible levels of response in each dimension (absence
of problems, moderate problems, extreme problems)
to assess self-perceived health status on the day of
completion. Utility indices based on the preferences
of the general population for each of the 243 states
defined by the descriptive system provide a summary
score of self-rated health on the 5 dimensions and
are available for various countries. They provide
values on a scale anchored at 0 (death) to 1 (full health)
and the Spanish value set was used to calculate the utility
score in the present study [17]. Patients also assess their
overall health on a vertical visual analogue scale (EQ-VAS)
from 0 to 100 where 0 represents the worst imaginable
health state and 100 represents the best imaginable health
state. The validated Spanish version of EQ-5D was used in
the present study [18].
The Physician’s In-Clinic UAS, which provides a rating
of the patient’s itching and hives (measured on a 0–6
scale), was also completed by the attending clinician,
with input from the patient, at both study visits. Further-
more, a 5 item Likert scale with responses of ‘Very mild’,
‘Mild’, ‘Moderate’, ‘Severe’, and ‘Very severe’ was used to
obtain the clinician and patient’s opinion on the overall
severity of their CSU in both study visits. In the final
visit, a categorical scale (Global Index of Change, or
GIC) was completed by physicians and patients to obtain
their opinion of the evolution of the CSU over the study
period. The GIC consisted of 13 response options ran-
ging from ‘Very much worse’ to ‘Very much improved’.
Patient opinions on the ease of completion and rele-
vance of the scale for assessing their urticaria were also
evaluated using a 5-point Likert scale.
Additional study variables collected included age, sex,
weight and height, ethnicity, educational level, presence
of chronic spontaneous urticaria (CSU), presence of
other types of urticaria associated with CSU, years since
onset of symptoms, years from diagnosis, number of
episodes in the previous year, presence of angiodema,
number of exacerbations in the previous year, whether
receiving treatment or not, presence of co-morbidities
associated with CSU, history of other atopic diseases, ex-
acerbation of CSU through NSAIDs, thyroid pathology,
and associated autoimmune conditions.
Sample size
Sample size was calculated to be able to detect a change
equivalent to 0.5 standard deviations in the overall score
of UAS7 (score range 0–42) between the two study visits
with the aim of being able to test the instrument’s re-
sponsiveness. It was estimated that a minimum of 128
patients would be required for validation of the Spanish
version of UAS7. A further 20% was added to take ac-
count of possible loss to follow-up and non-usable data
to give a total sample of approximately 150 patients.
Statistical analysis
Descriptive analysis of all variables was performed using
absolute numbers and frequencies in the case of catego-
rical variables and means or medians together with
standard deviations or interquartile ranges in the case of
continuous quantitative variables. The chi-square test
was used to study the relationship between qualitative
variables. Parametric (Student t test or ANOVA) or
non-parametric (U-Mann Whitney or Kruskal Wallis)
tests were used to study the relationship between con-
tinuous variables, depending on whether distribution
was normal or non-normal. A statistical significance
level of p < 0.05 was used in all analysis. Statistical ana-
lyses were carried out on the study population with valid
data, without any type of imputation of missing data.
The feasibility and psychometric properties (reliability,
validity, and responsiveness) of the UAS were analysed
using a variety of approaches.
Feasibility was assessed by analysing the proportion of
missing or unusable responses per item at each visit as
well as the proportion of patients with at least one miss-
ing or unusable response. We also calculated floor and
ceiling effects, i.e. patients scoring the minimum (0) and
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maximum scores for the UAS and UAS7 (6 and 42, re-
spectively) scores at each visit. Floor and ceiling effects
under 15% are usually considered acceptable [19].
The reliability of the questionnaire was assessed by es-
timating internal consistency (i.e., the degree of homo-
geneity of the 2 items forming the scale) and by
assessing test-retest reliability (i.e., the degree of stability
of the score when there are no changes in health status)
[20]. The internal consistency of the scale was evaluated
by calculating the Cronbach’s alpha for the overall in-
strument score. Test-retest reliability was assessed by
calculating the intraclass correlation coefficient (ICC)
for patients who, in the second study visit, declared that
their urticaria symptoms had not changed from baseline
using the global change item. For both Cronbach’s alpha
and the ICC, a value of 0.7 or more was considered to
indicate an acceptable level of reliability [21].
Construct validity, i.e. the degree to which the instru-
ment performs as expected in meeting a series of
pre-defined hypotheses, was assessed by evaluating its
convergent and discriminant validity, as well as its
known groups’ validity.
Convergent and discriminant validity refer to whether
the instruments shows expected patterns of correlations
with instruments measuring similar (convergent) and
dissimilar (discriminant) constructs. They were assessed
here by analysing the correlations of UAS7 scores with
scores on the EQ-5D-3 L and CU-Q2oL at baseline. We
also analysed the correlations between individual items
(itch and number of hives) on the UAS and dimension
scores on the CU-Q2oL. A series of hypotheses were de-
veloped regarding the expected pattern of correlations
between the different instruments. The UAS7 score was
expected to show lower correlations (r between 0.2 and
0.5) with the EQ-5D-3 L Index and VAS than with the
CU-Q2oL global score, as the latter is a
condition-specific measure. Higher correlations were ex-
pected between the UAS7 score and the EQ-5D-3 L di-
mensions of usual activities, pain/discomfort, and
anxiety/depression than with the dimensions of mobility
and self-care, as the former were considered more likely
to be affected by CSU. On the CU-Q2oL, we expected
moderate to high correlations (r = 0.5–0.8) between the
UAS7 score and all dimensions of the CU-Q2oL, but we
expected particularly high correlations between the itch
items on the two questionnaires.
Known groups’ validity was assessed by determining
the extent to which the instrument discriminated
between patients according to their self-rating on the
global CSU severity scale. The comparison was per-
formed using ANOVA and between group effect sizes,
which were calculated as the difference between group
means divided by the pooled standard deviation. Effect
sizes were classified as small (ES of approximately 0.20),
moderate (ES of 0.50) or large (0.80 or more) [22]. In
addition, scores were calculated for the UAS7 according
to the clinician rating on the In-Clinic UAS at the first
visit using the categorization proposed by Mathias et al.
of < 4, 4, 5, 6 points [11].
Responsiveness was investigated by analysing the magni-
tude of the change in the UAS7 score corresponding to
different levels of patient- and clinician-reported improve-
ment on the global urticaria rating scale. The global index
of change was also used for this analysis.
Finally, the MID for the UAS7 score was estimated in
several ways, using both anchor- and distribution-based
approaches [23]. For the anchor-based approach, clin-
ician and patient ratings of the overall severity of CSU
were used as the reference and a linear regression model
was constructed to estimate the score change on the
UAS and UAS7 corresponding to a one category shift on
the scale between the two visits. Patient ratings on the
GIC were also used as an anchor in an alternative
model. Distribution-based MIDs were estimated based
on the standard error of measurement (SEM) and stan-
dardised effect size (SES) using values of 1 SEM and 0.5
SES, as recommended [23].
Results
Data from a total of 166 patients meeting inclusion
criteria were available for analysis. All patients were re-
cruited consecutively as specified in the study protocol.
Table 1 shows the demographic and clinical character-
istics of the study population at baseline: 65.7% were fe-
male and mean (SD) age was 48.8 (14.3) yearsPatients
had a median of > 2 years with symptoms of CSU and
96% was being treated for CSU at the time of the visit.
Score distributions, feasibility, and reliability
Table 2 shows the data relating to the instrument’s feasi-
bility and reliability, as well as the mean scores and score
distributions at baseline. Mean (SD) for the UAS7 at
baseline was 16.4 (10.5) and there were 15% of patients
with missing values. Ninety-one percent of patients
found the UAS-7 ‘easy’ or ‘very easy’ to complete while
71% considered it ‘appropriate’ or ‘very appropriate’ to
measure their health status in relation to their urticaria.
Floor and ceiling effects were 5.4 and 1.2%, respectively.
Cronbach’s alpha for the UAS7 score was 0.83 and the
intra-class correlation coefficient in the test-retest
sample was 0.84.
Convergent and discriminant validity
The pattern of correlations between the UAS and EQ-5D
and CU-Q2oL at baseline was generally as expected
(Table 3). Convergence with the generic instrument was
somewhat weaker than with the disease-specific measure.
Almost all of the correlations with the CU-Q2oL were
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statistically significant both between summary scores and
at the level of individual dimensions, and correlation coef-
ficients tended to be higher than those with the EQ-5D.
The strongest correlations between the CU-Q2oL and the
UAS were seen between the UAS itching item and the
CU-Q2oL itching item (as expected) and summary score
(0.574 and 0.628, respectively). On EQ-5D, as expected,
the highest correlations were with the dimensions of pain
/ discomfort, usual activities, and anxiety / depression, but
only the UAS itch item and overall score showed statisti-
cally significant correlations with the EQ-5D.
Known groups’ validity
Known groups’ validity was demonstrated through the
instrument’s capacity to discriminate between groups
classified according to patient- and clinician-perceived
overall urticaria severity. UAS7 scores increased with in-
creasing severity of urticaria and with a statistically sig-
nificant linear trend (p < 0.0001 for between-group
differences in both cases) and moderate to large
between-group effect sizes (Table 4). A similar trend was
seen when patients were categorised according to the
clinician rating on the UAS at the first visit as < 4, 4, 5,
6, with corresponding mean (SD) UAS7 scores of 13.3
(9.3) for < 4 vs 21.6 (9.6), 19.2 (8.8), and 22.5 (14.6) for
the 4, 5, and 6 categories, respectively; p = 0.0047 for lin-
ear trend (data not shown).
Table 1 Study population baseline demographic and clinical
characteristics
Baseline
(n = 166)
Sex, female, n (%) 109 (65.7%)
Age (years), mean (SD) 48.8 (14.3)
Body mass index, mean (SD) 26.6 (4.6)
Education, n (%):
No formal education 5 (3.2%)
Primary 56 (35.4%)
Secondary 59 (37.3%)
Higher 38 (24.1%)
Urticaria associated with CSU 65 (39.6%)
Symptomatic Dermographism 49 (75.4%)
Delayed pressure 19 (29.2%)
Heat 7 (10.8%)
Cholinergic urticaria 10 (15.4%)
Years since first appearance of symptoms, mean (SD) 2.2 (0.1-51.3)
Years since diagnosis of urticaria, mean (SD) 1.1 (0-24.2)
Nº of episodes in the prior year, median (range) 2 (0-36)
Angioedema during any episode, n (%) 77 (47.0%)
Receiving treatment for CSU, n (%) 153 (96.2%)
Patients with comorbidities associated with CSU, n (%) 85 (51.5%)
SD standard deviation, CSU chronic spontaneous urticari
Table 2 Score distributions, feasibility, and reliability of the
UAS7 score
Hives Itching UAS7
Baseline scores and distributions
Mean (SD) 7.2
(5.8)
9.3
(5.6)
16.4
(10.5)
Median (range) 7
(0-21)
8
(0-21)
15
(0-42)
Missing values; floor and ceiling effects, n (%)
Missing 21
(12.7%)
21
(12.7%)
25
(15.1%)
Minimum score (floor) 22
(13.3%)
9
(5.4%)
9
(5.4%)
Maximum score (ceiling) 4
(2.4%)
6
(3.6%)
2
(1.2%)
Reliability
Internal consistency assessed
using Cronbach’s alpha (95% CI)a
0.83
(0.721 – 0.895)
Test-retest reliability, asessed
using ICC (95% CI)
0.84
(0.735 – 0.906)
SD standard deviation, Min minimum, Max maximum, ICC Intraclass correlation
coefficient. 95% CI 95% confidence interval. Missing values defined as number
and proportion of patients with at least one missing response. aTest-retest
reliability analysis performed in patients reporting no or minimal change in
urticaria status at visit 2
Table 3 Convergent validity of the UAS7 score. Pearson
correlation coefficients with EQ-5D and CU-Q2oL summary
scores and dimensions at baseline (statistically significant
correlations at p < 0.05 in bold)
UAS7
Hives Itch Overall
EQ-5D-3L
Mobility -0.030 0.037 0.005
Self-care 0.066 0.025 0.055
Usual activities 0.147 0.287 0.243
Pain/discomfort 0.143 0.251 0.218
Anxiety/depression 0.076 0.238 0.162
EQ VAS -0.111 –0.299 –0.222
EQ Índex -0.148 –0.301 –0.247
CU-Q2oL
Itch 0.606 0.574 0.628
Swelling 0.289 0.360 0.334
Impact on life activities 0.366 0.474 0.450
Sleep Problems 0.286 0.422 0.383
Limits 0.260 0.395 0.343
Looks 0.168 0.341 0.265
Overall score 0.379 0.510 0.471
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Responsiveness
The results of analysing responsiveness are shown in
Table 5 and are based on changes in patient ratings of
their overall urticaria severity between the two study
visits. Effect sizes were generally larger the greater the
magnitude of change. For example, a three-level change
in the global rating scale corresponded to an effect size
of 1.28 on the UAS7, which would represent a large ef-
fect size. This compares to an effect size of approxi-
mately 0.2 (a small effect size) on UAS7 for those
indicating no change or a one-level change in their con-
dition overall. There was essentially no difference in the
size of the change on the UAS7 score between patients
reporting identical levels of overall severity at the two
visits (mean [SD] change of 1.9 [8.9] points) and those
who reported an improvement equivalent to a change of
one category (e.g. from ‘moderate’ to ‘mild’) on the rat-
ing scale (mean [SD] change of 1.7 [7.0] points).
Minimal important difference
Distribution-based approaches to estimating a MID for the
UAS7 score suggested a range for the MID between 4.4
(based on the SEM) and 5.3 (based on half of one SES). A
more conservative estimate using the anchor-based ap-
proach indicates that the MID might be approximately 7–8
points based on the change in UAS7 score corresponding
to a two category shift on the Global Impression of Severity
scale, as shown in Table 5, and as derived from linear re-
gression modelling, which indicated that a two category
shift on the GIS would correspond to a change of 6.4 points
on the UAS7. Using the same criteria, on the Itching and
Hives sub-scales, the MID could be considered to be in the
range of 3.5–4 points.
Discussion
The UAS is widely used to assess CSU activity. To date,
however, there is no published information relating to
the psychometric performance of a Spanish version of
the once-daily version of the instrument. This study
remedies that and has shown that the Spanish version of
the UAS has very good reliability, construct validity, and
responsiveness. Given the international nature of many
clinical trials and epidemiological studies today, it is of
considerable importance to test and demonstrate the
psychometric properties of other language versions of
PROs such as the UAS and to compare results with
those for other language versions.
The fact that the UAS is a relatively simple instrument
may facilitate its adaptation and use in other languages
as well as tending to produce relatively robust psy-
chometric characteristics. In the present study, 91% of
patients found the instrument ‘easy’ or ‘very easy’ to
complete, attesting to the simple nature of the question-
naire. On the other hand, while 71% considered it “ap-
propriate” or “very appropriate” to measure their health
status and disease activity in relation to their urticaria,
30% rated the questionnaire as being of only ‘intermedi-
ate’ relevance or less. This suggests that patients might
prefer other aspects of their condition to be included.
In terms of reliability, the Spanish version of the
once-daily UAS shows good levels of internal
consistency and test-retest reliability which exceeded the
value of 0.70 which is typically considered an acceptable
threshold [21]. Earlier testing of the once-daily version
did not include evaluation of its reliability [9] and reli-
ability testing of the twice-daily version showed similar
results to those reported here for internal consistency
but somewhat poorer results for test-reliability, with an
ICC for the global UAS7 score of 0.66 [11].
Table 4 Known groups’ validity for the UAS7 score: mean
scores for different patient-rated categories of overall CSU
severity and corresponding between-group effect sizes
Hives Itch Global Between
group
effect size
Very mild (n = 20) 2.10 (2.90) 4.26 (4.42) 6.47 (6.69)
Mild (n = 32) 4.81 (5.45) 7.48 (4.43) 12.40 (8.43) 0.76
Moderate (n = 58) 7.74 (4.37) 9.93 (5.0) 17.62 (8.30) 0.63
Severe/intense
(n = 28)
9.61 (5.83) 11.52 (5.88) 21.04 (11.36) 0.36
Very severe /intense
(n = 7)
17.71 (3.35) 16.63 (5.32) 33.86 (7.84) 1.19
p < 0.0001 for between group differences
Table 5 Responsiveness of the UAS7 score: mean score
changes and effect sizes based on change in patient ratings of
overall urticaria severity
Difference between visits
in patient rating of
overall urticaria severity
Hives Itch Global
– 3 category change (n = 4) –7.6 (5.6) –7.2 (6.3) –15.0 (11.8)
ES: 1.39 ES: 1.14 ES: 1.28
– 2 category change (n = 16)a –3.7 (5.3) –4.3 (6.3) –8.3 (11.2)
ES: 0.69 ES: 0.68 ES: 0.74
– 1 category change (n = 47) –1.1 (4.2) –0.7 (5.2) –1.9 (8.9)
ES: 0.26 ES: 0.13 ES: 0.21
No change (n = 59) –0.7 (3.9) –0.9 (4.0) –1.7 (7.0)
ES: 0.18 ES: 0.23 ES: 0.25
+ 1 category change (n = 13) 2.3 (2.6) -0.5 (4.6) 2.3 (4.6)
ES: 0.90 ES: 0.12 ES: 0.51
+ 2 category change (n = 2) –1.5 (4.9) 1.5 (3.5) –3.0 (8.5)
ES: 0.30 ES:0.42 ES: 0.35
aFor example, a two category change would mean moving from ‘moderate’ to
‘very mild’, or ‘Very severe’ to ‘Moderate’
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The Spanish version of the UAS also demonstrated ac-
ceptable convergent validity, as our a priori hypotheses
regarding the pattern of correlations between them and
the EQ-5D and CU-Q2oL were generally satisfied. As
predicted, correlations were higher between the UAS
and the disease-specific CU-Q2oL than with the generic
HRQOL measure EQ-5D. The UAS itch severity
sub-scale was found to be more often statistically signifi-
cantly correlated with EQ-5D dimensions and summary
scores than the scale measuring number of hives, sug-
gesting that itch is likely to have a greater impact on
overall quality of life, as assessed by EQ-5D. The UAS
itch severity item also showed the highest correlation
with the EQ-5D pain/discomfort dimension, as would be
expected. The moderate correlations observed here be-
tween the UAS7 and the CU-Q2oL also confirm Koti et
al’s contention that disease activity only moderately cor-
relates with QOL impairment in patients with CSU [24].
Interestingly, the Looks dimension of the CU-Q2oL
showed the weakest correlation with disease activity
though this may be connected to the location of the
hives, which is something we did not investigate in the
present study.
This study also provides evidence of the Spanish ver-
sion’s responsiveness, with effect sizes for UAS7 scores
increasing as patients indicated larger degrees of change
in overall urticaria severity. The effect sizes observed in
this study were somewhat smaller than those reported
by Mathias et al. [11] for the twice-daily version of the
UAS using data from a clinical trial. They reported SES
ranging from 0.78 to 1.12 in the placebo arm and from
1.28 to 2.88 in the treatment arms. This compares with,
for example, an effect size of 0.74 in our study for pa-
tients reporting a two-level improvement in their global
rating of disease severity. Given that our study included
a range of patients many of whom were already on treat-
ment when they entered the study, it is perhaps to be
expected that effect sizes would be smaller.
Our suggested MID of 7–8 points for the UAS7
score is slightly lower than the estimates of 9.5 to 10.5
provided by Mathias et al. based on data from several
clinical trials [11, 12]. This may be due to differences
in study design and to the anchors used to estimate
MIDs. For example, Mathias et al. used changes on
the P-UAS, Dermatology Quality of Life Index and
EQ-5D as anchors, whereas we focused on overall
changes in urticaria severity as perceived by patients.
They also used data from clinical trials while our data
was collected from patients treated in usual clinical
practice. Our sample size was smaller and the number
of patients in the responsiveness analysis showing a
two-category change was low (n = 16). Additional work
on a MID for the UAS7 in clinical practice would
therefore be advisable.
Other limitations of the present study include the fact
that responsiveness was not assessed using a before and
after, interventional design. Nevertheless, based on pa-
tients’ global ratings of the severity of their condition
and of change in their condition, we found evidence that
the instrument is able to detect changes in patients’
urticaria status. Another limitation is that no external or
objective measure of disease severity was available to
provide a reference for testing of known groups’ validity,
which meant we had to rely on patient and investigator
ratings of overall disease severity using a single item
categorical scale.
Conclusion
The Spanish version of the UAS score has demonstrated
a robust psychometric performance in patients with
CSU managed in conditions of usual care. It can there-
fore be considered a suitable instrument to assess dis-
ease activity in Spanish-speaking patients in clinical
practice. The Spanish version’s reliability and validity are
similar to those reported for other language versions of
the once-daily and twice-daily variants of the UAS.
Appendix
Spanish version of the Urticaria Activity Score (UAS)
Instrucciones
 Conteste a cada pregunta lo mejor que pueda.
 No hay respuestas correctas ni incorrectas.
 En cada pregunta, escoja la respuesta que mejor se
ajuste a su experiencia.
 Al responder a las preguntas, piense en las últimas
24 horas. Marque solo una respuesta.
1. ¿Cuántos habones ha tenido en las últimas 24
horas?
0 No he tenido ningún habón o roncha
1 He tenido menos de 20 habones o ronchas
2 He tenido entre 20 y 50 habones o ronchas
3 He tenido más de 50 habones o bien extensas zonas con
habones confluentes o que se juntan entre ellos
Habones o ronchas son manchas rojas que pican, que
se hinchan y que desaparecen rápidamente (en horas) en
una zona del cuerpo para aparecer en otra zona del
cuerpo en los sucesivos minutos u horas. Cuente cada
habón por separado aunque tenga varios agrupados.
2. Valore entre 0 y 3 la intensidad del picor o prurito
que ha tenido durante las últimas 24 horas
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0 No he tenido picor o prurito
1 Leve (presente pero que no molesta)
2 Moderado (molesta pero no interfiere con la actividad diaria y
con el sueño)
3 Intenso (picor o prurito grave que es capaz de interferir con la
actividad diaria y con el sueño)
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